PharmatrophiX Selected for Landmark UCSF-led platform trial in rare neurodegenerative disease; Unveils New Data at Tau Global Conference
- Posted on May 14, 2026
PharmatrophiX unveiled preclinical data at the Global Tau Conference further supporting evidence that LM11A-31 is a multi-action shield for the brain's connections... Read More
p75 neurotrophin receptor modulation in mild to moderate Alzheimer’s disease
- Posted on May 17, 2024
The 26-week Phase 2a trial met its primary endpoint for safety and tolerability, with biomarker and imaging signals supporting further study.... Read More
Targeting Upstream Neurodegeneration: LM11A-31 in Alzheimer’s Disease and PSP
- Posted on May 7, 2026
David Setboun, Pharm.D., MBA, CEO of PharmatrophiX, and Frank M. Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology.... Read More
A better Alzheimer’s drug?
- Posted on Feb 25, 2026
Stanford Medicine profiles LM11A-31 as a synapse-protective approach to slowing neurodegeneration.... Read More
p75 receptor modulation slows biomarkers and preserves visuospatial function
- Posted on Dec 2, 2025
CTAD coverage reports p-tau217 and synaptic-proteome signals over 26 weeks.... Read More
New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
- Posted on Apr 3, 2025
NIA summarizes safety and biomarker findings supporting larger LM11A-31 trials.... Read More
Alzheimer’s from a New Angle
- Posted on Feb 11, 2016
Dr. Frank Longo on hope, innovation, and a radical departure from traditional Alzheimer’s research... Read More